Plain-English translation of NCT06699849 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , which is a natural protein found in human blood, to see if it can help people with sickle cell disease recover more quickly from vaso-occlusive crises—the severe, sudden pain episodes that happen when blood vessels become blocked. Researchers want to understand whether this treatment is safe and whether it actually shortens the time it takes for the crisis to get better. About 70 people will participate in this study.
Vaso-occlusive crises are one of the most painful and disruptive complications of sickle cell disease, and current treatments mainly focus on managing pain rather than speeding up recovery. This trial is exploring whether the medication can target the underlying biology of these crises to help patients heal faster and spend less time in severe pain.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would come to the hospital or clinic during an active pain crisis and receive the medication (or placebo) by IV infusion. Some participants will receive one dosing schedule of the treatment, others will receive a different schedule, and some will receive a placebo to help researchers compare results. The study team will monitor how quickly your pain improves, check your safety with blood tests and physical exams, and track how the medication moves through your body over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States